KLOW

What it is: KLOW 80 mg is a co-formulated research blend containing four peptide components — GHK-Cu, BPC-157, TB-500, and KPV — supplied at a total net quantity of 80 mg per vial. It is positioned as an expansion of Prime Time Bio Labs' GLOW 70 mg blend (GHK-Cu, BPC-157, TB-500), with KPV added as the fourth component. Format: Ships as a lyophilized (freeze-dried) powder in a sealed, light-protected vial. Each vial carries a printed lot number for batch traceability, and the unit includes handling and reconstitution guidance for laboratory use. Composition breakdown: Prime Time Bio Labs' current product page confirms the four components and the 80 mg total but does not publish the individual mg amount of each peptide within the blend. A commonly cited industry convention for "KLOW" products elsewhere is 50 mg GHK-Cu / 10 mg BPC-157 / 10 mg TB-500 / 10 mg KPV — but that figure has not been confirmed against this specific product's documentation, so it is not stated as a Prime Time Bio Labs specification here. Order quantity: Sold as a single "Standard" unit per vial; no minimum order quantity. Bulk pricing is available on select bundles for qualified research institutions by contacting the company directly.

KLOW 80 mg combines four independently studied peptides, each associated with a different area of laboratory research. The following describes what has been studied about each component individually — none of it is evidence that the combined KLOW formulation itself produces these effects, and none of it describes human outcomes. GHK-Cu is a naturally occurring copper-binding tripeptide. Laboratory and preclinical literature has examined its role in fibroblast activity, collagen and elastin synthesis, and tissue-remodeling pathways, largely in cellular and animal models. BPC-157 is a synthetic peptide that has been investigated primarily in small-animal and in-vitro models, with published reviews noting that efficacy has not been established in human subjects and that translational and regulatory questions remain open. TB-500 is marketed industry-wide as a thymosin beta-4–related material, though suppliers are not consistent about whether the material sold under this name is the full-length peptide or a shorter fragment. Prime Time Bio Labs' own documentation does not currently specify which identity applies to this product — that detail should come from the COA/manufacturing specification, not from convention. KPV is a short peptide corresponding to the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH). It is commonly discussed in supplier and research literature in connection with anti-inflammatory research pathways, again primarily at the preclinical and in-vitro level. Blend-level evidence: No published study identified examines the four-peptide KLOW combination as a single formulation. Research on each component individually does not establish the activity, stability, or safety profile of the combined blend, and should not be read as evidence that the finished KLOW product produces any specific effect. This product is intended strictly for laboratory and in-vitro research use, not for human or animal application.

Every batch of KLOW 80 mg undergoes third-party testing by HPLC (high-performance liquid chromatography) and mass spectrometry before release. HPLC is used to assess purity, while mass spectrometry supports identity confirmation of the peptide material. A Certificate of Analysis (COA) is issued for the specific lot number shipped and is available for download after purchase. The current batch on file: Lot PTBL08312026, reporting 99% purity, analyzed 9/2/2026. A purity and identity result on a COA confirms what the analytical method actually measures — it does not establish safety, sterility, or efficacy, and it is not evidence for how the material would behave in any biological system. Researchers should always confirm that the COA they're relying on matches the lot number printed on the vial in hand.

KLOW 80 mg is sold strictly for laboratory and research use. It is not a drug, food, or cosmetic product, has not been evaluated by the FDA, and is not intended for human or animal consumption, diagnostic use, or therapeutic use of any kind. It should be handled only by qualified researchers in an appropriate laboratory setting.